MedTrace Logo

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

NCT03680378 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2020-07-14

No results posted yet for this study

Summary

The primary objective of this study is to measure and compare the concentration of AAI101 and cefepime in bronchial epithelial lining fluid (ELF) and plasma following administration of cefepime/AAI101 combination in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

Cefepime 2 gram

Combination of cefepime 2 gram with AAI101 1 gram

Sponsors & Collaborators

  • Allecra

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680378 on ClinicalTrials.gov